We break down five of the week’s key pharma news stories.
CureVac comes up short
New data opens up potential role for COVID-19 antibody therapies
Questions remain over potential role of new depression therapy
Aduhelm approval glosses over Biogen's questionable investments
GSK boards the TIGIT train, but can it get upgraded?
To read more Friday Five articles, click here.